



FDA ADVISORY
No. **2021-0502**

05 MAR 2021

TO: GENERAL CONSUMING PUBLIC

SUBJECT: Public Health Warning Against the Purchase and Use of Cosmetic Product BABYFLO® BABY COLOGNE PINK FANTASY Containing Banned Ingredient/s

The Food and Drug Administration (FDA) warns the public from purchasing and using the adulterated cosmetic product **BABYFLO® BABY COLOGNE PINK FANTASY** which tested and found to contain presence of **METHANOL**. Such ingredient is not allowed to be part of a cosmetic product as per ASEAN Cosmetic Directive. The table below indicates the particulars of the adulterated cosmetic product/s:

PRODUCT DETAILS	PRODUCT IMAGE/S
<p>Name of Manufacturer/ Local Company Responsible for Placing the Product in the Market: Philusa Corporation</p> <p>Address: #28 Shaw Boulevard, Pasig City</p> <p>Country of Manufacture: Philippines</p> <p>Lot/Batch Number: C00192 Mfg. Date: 021820 Exp. Date: 021823</p>	

The aforementioned adulterated product is found to be non-compliant with the existing standards, and, thus pose potential hazards to the consuming public. Acute and chronic exposure of humans to Methanol by inhalation or ingestion may result in visual disturbances, such as blurred or dimness of vision, leading to blindness. Neurological damage, specifically permanent motor dysfunction, may also result. Contact of skin with methanol can produce mild to severe dermatitis in humans.

In light of the foregoing, the public is advised not to purchase the aforementioned unauthorized adulterated cosmetic product. Always check if a product is notified with



the FDA by using the FDA Verification Portal feature accessible at <https://verification.fda.gov.ph> which may be used by typing in the name of the product before the purchase and/or using the cosmetic products.

All concerned establishments are warned not to distribute adulterated cosmetic products.

All FDA Regional Field Offices and Regulatory Enforcement Units, in coordination with law enforcement agencies and Local Government Units, are requested to ensure that violative products are not sold or made available in the market or areas of their jurisdiction.

To report any sale, distribution, complaint and/or adverse event on the use of the violative cosmetic product, the online reporting facility, eReport can be accessed at ereport@fda.gov.ph, or call us at the Center for Cosmetics and Household/Urban Hazardous Substances Regulation and Research (CCHUHSRR) hotline **(02) 8857-1900 loc. 8113 or 8107**.

Dissemination of this advisory to all concerned is hereby requested.


ROLANDO ENRIQUE D. DOMINGO, MD
Director General

DTN 20210302111711